Before you get too excited about Friday's move, "Mad Money" host Jim Cramer puts it in context.» Read More
Bill Ackman isn't the only hedge fund manager who likely made big money on the Allergan deal.
The deal beats the unsolicited bid last spring of above $50 billion from Valeant, which teamed with Bill Ackman.
An unconfirmed rumor appears to be having a major impact on Wal-Mart options trading.
Bill Ackman partnered with another hedge fund to buy a 10 percent stake in animal health company Zoetis, Dow Jones reported.
Herbalife CEO John DeSimone spoke to CNBC's "Halftime Report" in an exclusive interview.
Lower guidance shows Herbalife faces challenges outside the relentless attacks from activist investors, says CNBC's Jim Cramer.
Herbalife reported earnings that missed expectations and offered a sales outlook that was well below forecasts, sending shares plunging 13 percent.
The building has ruled over New York real estate, but now its sales may be coming back down to Earth.
Discovery Capital has been battered by volatility, according to a report that disclosed losses of more than 20 percent in one of its main funds.
Herbalife CEO, Michael Johnson, talks about the FTC investigation and Bill Ackman accusations in a recent interview with Los Angeles Magazine.
Wall Street is spending more on the midterms than ever before—particularly in support of the GOP—but it's not from whom you might think.
Jim Cramer takes on activist calls to CEOs strong performing companies, and suggests they realign their attention
U.S. stocks ended about 2 percent higher on Wednesday as markets extended gains on the FOMC minutes and recovered from Tuesday's selloff.
Founder and CEO, Pershing Square Capital Management
The SEC accuses two men of insider trading ahead of Bill Ackman's announcement that his Pershing Square fund had taken a short position on Herbalife.
As CEO of his own soon-to-be public company, Bill Ackman will use a dual share-class structure that has been considered unfriendly to investors.
U.S. stocks closed down on Friday, breaking five weeks of consecutive gains as investors awaited the Federal Reserve's announcement next Wednesday.
Take a look at some of Friday's midday movers:
William Ackman criticized Allergan's board of directors, urging them to "wake up" and at least listen to potential purchaser Valeant Pharmaceuticals.
Securities regulators are looking into the joint bid by Valeant Pharmaceuticals and activist investor Bill Ackman for Allergan, Dow Jones reported.